Mode
Text Size
Log in / Sign up
N/A Completed N=71 Randomized Single-blind Treatment

Clinical Performance Comparison of Several Different Contact Lenses

Source: ClinicalTrials.gov NCT00912028 ↗
Enrolled (actual)
71
Serious AEs
0.0%
Results posted
Apr 2014
Primary outcomePrimary: Limbal Hyperemia (Redness) — 40; 14; 24; 12 eyes

Summary

The purpose of the study is to evaluate the possible benefits of second generation silicone hydrogel contact lenses.

Outcome Measures

OutcomeResultp-value
PRIMARY
Limbal Hyperemia (Redness)
46; 16; 18; 10; 4; 12
PRIMARY
Limbal Hyperemia (Redness)
46; 16; 18; 10; 4; 12
PRIMARY
Bulbar Hyperemia (Redness)
45; 11; 23; 12; 13; 9
PRIMARY
Bulbar Hyperemia (Redness)
45; 11; 23; 12; 13; 9
PRIMARY
Corneal Staining
33; 8; 10; 19; 16; 18
PRIMARY
Corneal Staining
33; 8; 10; 19; 16; 18

Eligibility Criteria

Inclusion Criteria

Subjects must:

  • be existing soft contact lens wearers of the study control lenses
  • require a distance visual correction in both eyes
  • have a contact lens spherical distance requirement between -1.00 diopters (D) and -8.00D in both eyes
  • have astigmatism less than or equal to 1.00D in both eyes
  • be able to wear lenses available for this study
  • be corrected to a visual acuity of 6/9 (20/30) or better in each eye
  • have normal eyes with no evidence of abnormality or disease

Exclusion Criteria

Subject are excluded for the following reasons:

  • monovision corrected
  • worn lenses extended wear in the last 3 months.
  • require concurrent ocular medication
  • grade 3 or 4 abnormalities
  • grade 3 corneal staining in more than two regions
  • anterior ocular surgery
  • any other ocular surgery or injury within 8 weeks prior to study enrollment
  • abnormal lachrymal secretions
  • pre-existing ocular irritation that would preclude contact lens fitting
  • corneal irregularities
  • Polymethyl methacrylate (PMMA) or Rigid Gas Permeable (RGP) lens wear in past 12 weeks
  • any systemic illness which would preclude contact lens wear
  • diabetes
  • infectious or immunosuppressive disease
  • pregnancy or lactating, or planning pregnancy at time or enrollment
  • participating in a concurrent clinical study or within last 60 days
  • allergy to the standardized study care solution
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00912028). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search